Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. [electronic resource]
Producer: 20040609Description: 583-91 p. digitalISSN:- 1083-8791
- Adult
- Animals
- Antigens, CD -- analysis
- Antigens, CD34 -- analysis
- Antilymphocyte Serum -- adverse effects
- Autoimmune Diseases -- therapy
- B-Lymphocytes -- chemistry
- Blood Component Removal
- Epstein-Barr Virus Infections -- etiology
- Female
- Flow Cytometry
- Granulocyte Colony-Stimulating Factor -- pharmacology
- Herpesvirus 4, Human -- isolation & purification
- Horses
- Humans
- Immunosuppressive Agents -- adverse effects
- Killer Cells, Natural -- chemistry
- Lymphoproliferative Disorders -- etiology
- Male
- Middle Aged
- Multiple Sclerosis -- therapy
- Neutrophils -- chemistry
- Opportunistic Infections -- etiology
- Peripheral Blood Stem Cell Transplantation -- adverse effects
- Platelet Transfusion
- Rabbits
- Scleroderma, Systemic -- therapy
- T-Lymphocytes -- chemistry
- Transplantation Conditioning -- adverse effects
- Transplantation, Autologous
No physical items for this record
Publication Type: Case Reports; Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.